Name: CAI Income Statement - Caris Life Sciences Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

CAI - Caris Life Sciences, Inc.

USD | NASDAQ | Healthcare

CAI Income Statement - Caris Life Sciences Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q3 FY 24	Q2 FY 24
Revenues
Revenues	216.2	292.9	216.8	181.4	120.9	101.6	100.0
Cost of Revenue	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-
Operating Expenses
Research & Development	31.3	31.8	21.6	25.0	23.1	27.6	24.8
Selling General & Administrative	-	-	-	-	-	-
Operating Income
Operating Income	5.3	88.4	32.6	(18.0)	(58.0)	(60.8)	(67.0)
Non-Operating
Interest Income	6.8	7.0	7.4	1.6	0.5	1.7	2.6
Interest Expense	12.8	11.4	13.5	19.2	12.8	13.8	13.7
Tax & Net
Income Tax Expense	(0.1)	0.0	0.0	0.0	0.0	0.0	0.0
Net Income From Continuing Ops	(0.5)	82.0	24.3	(71.8)	(102.6)	(67.7)
Per Share
EPS Basic	0.00	-	0.09	(7.97)	(3.57)	(2.59)	(2.54)
EPS Diluted	0.00	-	0.08	(7.97)	(3.57)	(2.59)	(2.54)
Supplementary Data
EBITDA	10.3	92.7	37.5	(11.6)	(50.9)	(50.3)	(55.4)
EBIT	5.3	88.4	32.6	(18.0)	(58.0)	(60.8)	(67.0)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	TTM	FY2025	FY2024	FY2023
Revenues
Revenues	907.3	812.0	412.3	306.1
Cost of Revenue	-	-	-	-
Gross Profit	-	-	-	-
Operating Expenses
Research & Development	109.8	101.6	113.9	116.9
Selling General & Administrative	-	-	-	-
Selling & Marketing	172.7	167.5	152.6
Operating Income
Operating Income	108.3	45.1	(257.1)	(319.6)
Non-Operating
Interest Income	22.8	16.5	7.1	11.3
Interest Expense	56.9	56.9	50.0	31.6
Income From Equity Investments	-	-	-
Tax & Net
Income Tax Expense	(0.1)	0.0	0.0	0.0
Net Income From Continuing Ops	34.0	(68.1)	(281.9)	(341.4)
Net Income From Discontinued Ops	-	-	-
Per Share
EPS Basic	(1.46)	(3.22)	(10.66)	(13.24)
EPS Diluted	(1.46)	(3.22)	(10.66)	(13.24)
Shares Basic	282.6	167.2	35.5	34.9
Supplementary Data
EBITDA	129.0	67.7	(208.2)	(270.6)
EBIT	108.3	45.1	(257.1)	(319.6)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)